Ophiobolin A impacts mitochondrial redox biology in an epithelial-mesenchymal transition (EMT)-specific manner

Read full text
Authors: H. M. Parker, Yongfeng Tao, Jenna L. Tobin, Kayla L. Haberman, Samantha J. Davis, Emily R. York, Alysia E. Martinez, Nobuyuki Matsumoto, Jaquelin Aroujo, Jun Hyoung Park, Bernd Zechmann, Benny Abraham Kaipparettu
+7 more Angela Boari, Christie M. Sayes, Antonio Evidente, Alexander V. Kornienko, Benjamin F. Cravatt, Daniel Romo, Joseph H. Taube
Cited by: 1
References: 68

Abstract

Breast cancer progression is facilitated by the epithelial to mesenchymal transition (EMT), generating cancer cells with enhanced metastatic capacity and resistance to chemotherapeutics. The fungus-derived sesterterpenoid natural produce compound, ophiobolin A (OpA), possesses nanomolar cytotoxic activity and a high therapeutic index, although its molecular targets and mechanism of action are not well characterized. Herein, we utilized a model of mammary epithelial cells and breast cancer cell lines with and without EMT features to characterize the mechanism of selectivity towards EMT(+) cells by OpA. Proteins interacting with OpA in EMT(+) cells, including mitochondrial glutathione transporter SLC25A40, were identified through via mass spectrometry. We utilized trans-mitochondrial cybrids to determine that mitochondria mediate sensitivity to OpA. Furthermore, we report effects on glycolysis, oxidative metabolism, and disruption of metabolite abundance in the TCA cycle. Antioxidant mechanisms are activated by OpA in EMT(+) cells via the NRF2-ARE pathway, verified by decreased cytotoxicity in EMT(+) cells pretreated with the NRF2 activator CDDO. Collectively, we conclude that OpA selectivity toward EMT is mediated by the mitochondria, and at sub-cytotoxic levels, generates a metabolic shift leading to cell death countered by antioxidant mechanisms.

Fields of Study & Subjects

Microbial Natural Products and Biosynthesis Plant-derived Lignans Synthesis and Bioactivity 14-3-3 protein interactions

Publication details

Journal / source
Cancer Cell International
Publisher
Springer Science and Business Media LLC
Volume
26
Issue
1
Pages
80–80
Publication date
14 January 2026
Language
EN